AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Back to search results

ALXAN

Summary

8-Etinylxanthines: potent dual-target-directed adenosine receptor antagonists with a beneficial neuroprotective function in Parkinson’s and Alzheimer’s disease.

Technology Benefits

New potent dual- and triple-target drugs for the treatment of PD and AD
Multi-target drug with improved compliance, less side effects, reduced toxicity
Significant advantages over combination therapy: more predictable pharmacology, reduced drug-drug interactions, less complex pharmacokinetics

Technology Application

these observations position tricyclic xanthine derivatives as ideal candidates for the treatment of neurodegenerative diseases such as PD and AD, but might also be suitable for the treatment of depression, addiction and restless legs syndrome.

Detailed Technology Description

This invention provides newly designed tricyclic xanthine derivatives which allow overcoming this problem. A variety of 69 derivatives were prepared and evaluated in radioligand binding studies at adenosine receptors and for their ability to inhibit monoamine oxidases. Potent dual-target-directed A1/A2A adenosine receptor antagonists were identified. Several compounds even showed triple-target inhibition.

Type of Cooperation

Licensing

Application Date

28/06/2011 00:00:00

Application No.

EP20070856895 20071219

Classes

- international:
A61K31/495; A61P25/00; C07D473/04; C07D473/06
- cooperative:
C07D473/04; C07D473/06

Others

Patent application

ID No.

1613

Country/Region

Germany

For more information, please click Here